Search

Background: The advancements in artificial intelligence and computational power have made deep learning an attractive tool for radiotherapy treatment planning. Deep learning has the potential to significantly simplify the trial‐and‐error process involved in inverse planning required by modern treatment techniques such as volumetric modulated arc therapy (VMAT). In this study, we explore the ability of deep learning to predict organ‐at‐risk (OAR) dose–volume histograms (DVHs) of left‐sided breast cancer patients undergoing VMAT treatment based solely on their anatomical characteristics. The predicted DVHs could be used to derive patient‐specific dose constraints and dose objectives, streamlining the treatment planning process, standardizing the quality of the plans, and personalizing the treatment planning. Purpose: This study aimed to develop a deep learning‐based framework for the prediction of organ‐specific dose–volume histograms (DVH) based on structures delineated for left‐sided breast cancer treatment. Methods: We used a dataset of 249 left‐sided breast cancer patients treated with tangential VMAT fields. We extracted delineated structures and dose distributions for each patient and derived slice‐by‐slice DVHs for planning target volume (PTV) and organs‐at‐risk. The patients were divided into training (70%, n = 174), validation (10%, n = 24), and test (20%, n = 51) sets. Collected data were used to train a deep learning model for the prediction of the DVHs based on the delineated structures. The developed deep learning model comprised a modified DenseNet architecture followed by a recurrent neural network. Results: In the independent test set (n = 51), the point‐wise differences in the slice‐by‐slice DVHs between the clinical and predicted DVHs were small; the mean squared errors were 3.53, 1.58, 2.28, 3.37, and 1.44 [×10−4] for PTV, heart, ipsilateral lung, contralateral lung, and contralateral breast, respectively. With the derived cumulative DVHs, the mean absolute difference ± standard deviation of mean doses between the clinical and the predicted DVH were 0.08 ± 0.04 Gy, 0.24 ± 0.22 Gy, 0.73 ± 0.46 Gy, 0.07 ± 0.06 Gy, and 0.14 ± 0.14 Gy for PTV, heart, ipsilateral lung, contralateral lung, and contralateral breast, respectively. Conclusions: The deep learning‐based approach enabled automatic and reliable prediction of the DVH based on delineated structures. The predicted DVHs could potentially serve as patient‐specific clinical goals used to aid treatment planning and avoid suboptimal plans or to derive optimization objectives and constraints for automated treatment planning. [ABSTRACT FROM AUTHOR]

The increase in high-precision radiation therapy, particularly volumetric-modulated arc therapy (VMAT), has increased patient numbers and expanded treatment sites. However, a significant challenge in VMAT treatment planning is the inconsistent plan quality among different planners and facilities. This study explored the use of dose-volume histogram (DVH) prediction tools to address these disparities, specifically focusing on RapidPlan (Varian Medical Systems) and PlanIQ (Sun Nuclear). RapidPlan predicts achievable DVHs and automatically generates optimization objectives. While it has demonstrated organ-at-risk (OAR) dose reduction benefits, the quality of the plan used to build its model significantly affects its predictions. On the other hand, PlanIQ offers ease of use and does not require prior model-building. Five planners participated in this study, each creating two treatment plans: one referencing RapidPlan and the other using PlanIQ. The planners had the freedom to adjust parameters while referencing the DVH predictions. The plans were evaluated using "Plan Quality Metric" (PQM) scores to assess the planning target volume excluding the rectum and OARs. The results revealed that RapidPlan-referenced plans often outperformed PlanIQ-based plans, with less interplanner variability. PlanIQ played a pivotal role in the construction of the RapidPlan model. This study is the first to compare plans generated by multiple planners using both tools. This study provides insights into optimizing treatment planning by considering the characteristics of both RapidPlan and PlanIQ. [ABSTRACT FROM AUTHOR]

Introduction: Voxel-based dosimetry offers improved outcomes in the treatment of hepatocellular carcinoma (HCC) with transarterial radioembolization (TARE) using glass microspheres. However, the adaptation of voxel-based dosimetry to resin-based microspheres has been poorly studied, and the prognostic relevance of heterogeneous dose distribution remains unclear. This study aims to explore the use of dose–volume histograms for resin microspheres and to determine thresholds for objective metabolic response in HCC patients treated with resin-based TARE. Methods: We retrospectively reviewed HCC patients who underwent TARE with Y-90-loaded resin microspheres in our institution between January 2021 and December 2022. Voxel-based dosimetry was performed on post-treatment Y-90 PET/CT images to extract parameters including mean dose absorbed by the tumor (mTD), the percentage of the targeted tumor volume (pTV), and the minimum doses absorbed by consecutive percentages within the tumor volume (D10, D25, D50, D75, D90). Assessment of metabolic response was done according to PERCIST criteria with F-18 FDG PET/CT imaging at 8–12 weeks after the treatment. Results: This study included 35 lesions targeted with 22 TARE sessions in 19 patients (15 males, 4 females, mean age 60 ± 13 years). Objective metabolic response was achieved in 43% of the lesions (n = 15). Responsive lesions had significantly higher mTD, pTV, and D25-D90 values (all p < 0.05). Optimal cut-off values for mTD, pTV, and D50 were 94.6 Gy (sensitivity 73%, specificity 70%, AUC 0.72), 94% (sensitivity 73%, specificity 55%, AUC 0.64), and 91 Gy (sensitivity 80%, specificity 80%, AUC 0.80), respectively. Conclusion: Parameters derived from dose–volume histograms could offer valuable insights for predicting objective metabolic response in HCC patients treated with resin-based TARE. If verified with larger prospective cohorts, these parameters could enhance the precision of dose distribution and potentially optimize treatment outcomes. [ABSTRACT FROM AUTHOR]

Background & Aims: The collimator angle significantly impacts radiation leakage between the multi-leaf collimator (MLCs) leaves. This study aims to examine dose-volume evaluation in planning target volume (PTV) and organs at risk (OARs) for Head & Neck patients undergoing volumetric-modulated arc therapy (VMAT) with 2.5 arcs and varying collimator angles. Materials & Methods: In this experimental study, five patients with nasopharyngeal cancer were selected for treatment with the VMAT method. CT images were prepared using a CT simulator and transferred to the treatment planning system. For optimizing VMAT plans, volume and dose constraints were applied to OARs and PTVs by the algorithm. Then, the doses were calculated using the AAA algorithm. Results: Although no significant differences were observed in DVH curves across different collimator angles, other parameters exhibited variations. Notably, in Head & Neck cancer patients, optimal values for dose conformity, homogeneity, MUs, and gradient index were found at collimator angles of 20° and 30°. Additionally, OAR sparing was favorable at these angles. Based on target coverage, homogeneity, and MUs, the collimator angles were optimized for VMAT planning. Conclusion: Our findings offer valuable guidance to clinical medical physicists in making informed decisions regarding collimator angles. The dosimetric analysis underscores the importance of selecting the optimal collimator angle for accurate PTV coverage.

Aim and Objectives: The study was conducted to to compare the dosimetric superiority between the Field in Field and Box techniques. Meterials and Methods: We have taken 22 Patients of Ca esophagus for our study from our Institute database. Patients were already treated Box (4 fields) plan. Retrospectively additional Field in Field (FIF) plan was created with Planning target volume (PTV) prescription dose of 59.4Gy in 33 fractions. Prescription dose of 95% of PTV was chosen for the comparison between two treatment planning strategies. The Dose volume histogram (DVH) was used to analyze and compare various plan quality index and doses to the organs at risk (OARs). For each patient, two treatment plans were created: Box 4FB and FIF. The parameters compared included the conformity index (CI), homogeneity index (HI), Conformation number (CN), DMean, DMax, V20Gy and V30Gy of the heart and lungs, and monitor units per fraction (MU/fr). Results: A paired t-test analysis significant differences (P < 0.05) between the two techniques in terms of the CI, HI, and CN when the FIF was applied. The Dmax of the PTV, lung, and spinal cord were also significantly better with the FIF. Moreover, the V20Gy of the significantly reduced when the FIF was used and the MU/fr was significantly decreased. The FIF technique enables better dose distribution in the PTV and reduces dose to OARs in esophageal radiotherapy. Conclusion: Although all plans were within acceptable limits, dosimetric comparison of different planning techniques revealed that FIF had statistically significant differences from Box planning technique in terms of planned target volume (PTV) coverage, OAR protection, HI, CI, CN, MU and treatment duration. From the aspect of treatment duration and MU parameters, FIF technique can be considered as an alternative planning option.

Purpose: To assess the impact of body dose on survival outcomes in nasopharyngeal carcinoma (NPC) patients and to create novel nomograms incorporating body dose parameters for predicting survival. Methods: 594 of non-metastasis NPC patients (training group, 396; validation group, 198) received intensity-modulated radiation therapy at our institution from January 2012 to December 2016. Patient characteristics, body dose parameters in dose–volume histogram (DVH) and hematology profiles were collected for predicting overall survival (OS) and progression-free survival (PFS). Nomograms for OS and PFS were developed using the selected predictors. Each nomogram was evaluated based on its C-index and calibration curve. Results: Body dose-based risk score for OS (RSOS), N stage, age, and induction chemotherapy were independent predictors for OS, with a C-index of 0.784 (95% CI 0.749–0.819) in the training group and 0.763 (95% CI 0.715–0.810) in the validation group for the nomogram. As for PFS, the most important predictors were the body dose-based risk score for PFS (RSPFS), N stage, and induction chemotherapy. C-index of PFS nomogram was 0.706 (95% CI 0.681–0.720) in the training group and 0.691 (95% CI 0.662–0.711) in the validation group. The two models outperformed the TNM staging system in predicting outcomes. Conclusions: Body dose coverage is a useful predictor of prognosis in clinical routine patients. The novel nomograms integrating body dose parameters can precisely predict OS and PFS in NPC patients. [ABSTRACT FROM AUTHOR]

Our study is motivated by radiation therapy design for cancer treatment. We consider large-scale problems with stochastic order constraints. We establish a general result about the form of the deepest cuts associated with events of positive probability which are used in the numerical approximation of the functional constraints. An efficient method using the deepest cuts is proposed for the numerical solution of problems with second-order dominance constraints and increasing convex order constraints. We the propose a new methodology for the radiation-therapy design for cancer treatment. We introduce a risk-averse optimization problem with two types of stochastic order relations and with coherent measures of risk and consider the effect of the risk models in three versions of the problem formulation. Additionally, we propose a method that creates flexible (floating) benchmark distributions when benchmark distributions are not given apriori or when the provided distributions lead to infeasibility. We devise a numerical method using floating benchmarks for solving the proposed risk-averse optimization models for radiation therapy design. The models and methods are verified by using clinical data confirming the viability of the proposed methodology and its efficiency. [ABSTRACT FROM AUTHOR]

Simple Summary: Postoperative radiotherapy can be associated with both early and late toxicity. In this retrospective analysis, we aimed to assess the prevalence of adverse events and their association with several dose–volume parameters. The results of our study showed that both rectum wall and rectum parameters within the range of 30–65 Gy presented significant association with acute ≥G2 gastrointestinal toxicity. On the other hand, the occurrence of late ≥G2 gastrointestinal toxicity was significantly associated only with rectum wall parameters, including V35–V54, V66–V69, and V71. Finally, the risk of experiencing late ≥G2 genitourinary adverse events was significantly associated with all bladder wall parameters between 30–54 Gy and all bladder parameters between 30–53 Gy. However, there was a clinically relevant risk of adverse events even in patients who adhered to commonly used dose constraints. This supports the conclusions of recent evidence showing that an early-salvage approach is preferable due to its non-inferior oncological outcomes. Although prostate cancer treatment is increasingly effective, its toxicities pose a major concern. The aim of our study was to assess the rate of adverse events (AEs) and the prognostic value of dose–volume histogram (DVH) parameters for the occurrence of treatment toxicity in patients treated with post-prostatectomy prostate bed radiotherapy (RT). The AEs were scored according to the CTCAE v.5.0. The rectum and bladder were contoured according to the RTOG Guidelines. The DVH parameters were assessed using data exported from the ECLIPSE treatment-planning system. Genitourinary (GU) and gastrointestinal (GI) toxicity were analysed using consecutive dose thresholds for the percentage of an organ at risk (OAR) receiving a given dose and the QUANTEC dose constraints. A total of 213 patients were included in the final analysis. Acute grade 2 or higher (≥G2) GU AEs occurred in 18.7% and late in 21.3% of patients. Acute ≥G2 GI toxicity occurred in 11.7% and late ≥G2 in 11.2% of the patients. Five patients experienced grade 4 AEs. The most common adverse effects were diarrhoea, proctitis, cystitis, and dysuria. The most significant predictors of acute ≥G2 GI toxicity were rectum V47 and V46 (p < 0.001 and p < 0.001) and rectum wall V46 (p = 0.001), whereas the most significant predictors of late ≥G2 GI AEs were rectum wall V47 and V48 (p = 0.019 and p = 0.021). None of the bladder or bladder wall parameters was significantly associated with the risk of acute toxicity. The minimum doses to bladder wall (p = 0.004) and bladder (p = 0.005) were the most significant predictors of late ≥G2 GU toxicity. Postoperative radiotherapy is associated with a clinically relevant risk of AEs, which is associated with DVH parameters, and remains even in patients who fulfil commonly accepted dose constraints. Considering the lack of survival benefit of postoperative adjuvant RT, our results support delaying treatment through an early salvage approach to avoid or defer toxicity. [ABSTRACT FROM AUTHOR]

Background: Dosimetry in radionuclide therapy often requires the calculation of average absorbed doses within and between spatial regions, for example, for voxel‐based dosimetry methods, for paired organs, or across multiple tumors. Formation of such averages can be made in different ways, starting from different definitions. Purpose: The aim of this study is to formally specify different averaging strategies for absorbed doses, and to compare their results when applied to absorbed dose distributions that are non‐uniform within and between regions. Methods: For averaging within regions, two definitions of the average absorbed dose are considered: the simple average over the region (the region average) and the average when weighting by the mass density (density‐weighted region average). The latter is shown to follow from the definition of mean absorbed dose according to the ICRU, and to be consistent with the MIRD formalism. For averaging between different spatial regions, three definitions follow: the volume‐weighted, the mass‐weighted, and the unweighted average. With respect to characterizing non‐uniformity, the different average definitions lead to the use of dose‐volume histograms (DVHs) (region average), dose‐mass histograms (DMHs) (density‐weighted region average), and unweighted histograms (unweighted average). Average absorbed doses are calculated for three worked examples, starting from the different definitions. The first, schematic, example concerns the calculation of the average absorbed dose between two regions with different volumes or mass densities. The second, stylized, example concerns voxel‐based dosimetry, for which the average absorbed‐dose rate within a region is calculated. The geometries studied include three 177Lu‐filled voxelized spheres, where the sphere masses are held constant while the material compositions, densities, and volumes are varied. For comparison, the mean absorbed‐dose rates obtained using unit‐density sphere S‐values are also included. The third example concerns SPECT/CT‐based tumor dosimetry for five patients undergoing therapy with 177Lu‐PSMA and six patients undergoing therapy with 177Lu‐DOTA‐TATE, for which the average absorbed‐dose rates across multiple tumors are calculated. For the second and third examples, analyses also include representations by histograms. Results: Example 1 shows that the average absorbed doses, calculated using different definitions, can differ considerably if the masses and absorbed doses for two regions are markedly different. From example 2 it is seen that the density‐weighted region average is stable under different activity and density distributions and is also in line with results using S‐values. In contrast, the region average varies as function of the activity distribution. In example 3, the absorbed dose rates for individual tumors differ by (1.1 ± 4.3)% and (−0.1 ± 0.4)% with maximum deviations of +34.4% and −1.4% for 177Lu‐PSMA and 177Lu‐DOTA‐TATE, respectively, when calculated as region averages or density‐weighted region averages, with largest deviations obtained when the density is non‐uniform. The average absorbed doses calculated across all tumors are similar when comparing mass‐weighted and volume‐weighted averages but these differ substantially from unweighted averages. Conclusion: Different strategies for averaging of absorbed doses within and between regions can lead to substantially different absorbed‐dose estimates. At reporting of radionuclide therapy dosimetry, it is important to specify the averaging strategy applied. [ABSTRACT FROM AUTHOR]

Simple Summary: We looked at the long-term quality of life of patients treated with modern radiotherapy for relapsed prostate cancer after initial surgery. By comparing the original radiotherapy treatment plans with the reported quality of life of the patients, we looked for correlations between the doses received by the healthy pelvic organs and patients' long-term quality of life. In contemporary radiotherapy practice, healthy organs are spared as much as possible from the high doses required to treat the cancer in order to avoid side effects. We were able to show that patient's quality of life may also be impacted by low doses to their pelvic organs. Therefore, it seems desirable that specific thresholds need to be established in the low dose spectrum as well in order to further improve patients' quality of life after radiotherapy. Since this is a complex endeavor requiring extensive research, we provide future researchers with our entire dataset in order to hopefully facilitate their work. Introduction: Prostate bed radiotherapy (RT) is a major affecter of patients' long-term quality of life (QoL). To ensure the best possible outcome of these patients, dose constraints are key for optimal RT planning and delivery. However, establishing refined dose constraints requires access to patient-level data. Therefore, we aimed to provide such data on the relationship between OAR and gastrointestinal (GI) as well as genitourinary (GU) QoL outcomes of a homogenous patient cohort who received dose-intensified post-operative RT to the prostate bed. Furthermore, we aimed to conduct an exploratory analysis of the resulting data. Methods: Patients who were treated with prostate bed RT between 2010 and 2020 were inquired about their QoL based on the Expanded Prostate Cancer Index Composite (EPIC). Those (n = 99) who received volumetric arc therapy (VMAT) of at least 70 Gy to the prostate bed were included. Dose-volume histogram (DVH) parameters were gathered and correlated with the EPIC scores. Results: The median age at the time of prostate bed RT was 68.9 years, and patients were inquired about their QoL in the median 2.3 years after RT. The median pre-RT prostate-specific antigen (PSA) serum level was 0.35 ng/mL. The median duration between surgery and RT was 1.5 years. The median prescribed dose to the prostate bed was 72 Gy. A total of 61.6% received prostate bed RT only. For the bladder, the highest level of statistical correlation (p < 0.01) was seen for V10-20Gy, Dmean and Dmedian with urinary QoL. For bladder wall, the highest level of statistically significant correlation (p < 0.01) was seen for V5-25Gy, Dmean and Dmedian with urinary QoL. Penile bulb V70Gy was statistically significantly correlated with sexual QoL (p < 0.05). A larger rectal volume was significantly correlated with improved bowel QoL (p < 0.05). Sigmoid and urethral DVH parameters as well as the surgical approach were not statistically significantly correlated with QoL. Conclusion: Specific dose constraints for bladder volumes receiving low doses seem desirable for the further optimization of prostate bed RT. This may be particularly relevant in the context of the aspiration of establishing focal RT of prostate cancer and its local recurrences. Our comprehensive dataset may aid future researchers in achieving these goals. [ABSTRACT FROM AUTHOR]

This work analyzed the dosimetric difference between the intensity modulated radiotherapy (IMRT), partial/single/double-arc volumetric modulated arc therapy (PA/SA/DA-VMAT) techniques in treatment planning for treating more than one target of lung cancer at different isocenters. IMRT and VMAT plans at different isocenters were created systematically using a Harold heterogeneous lung phantom. The conformity index (CI), homogeneity index (HI), gradient index (GI), dose-volume histogram and mean and maximum dose of the PTV were calculated and analyzed. Furthermore, the dose-volume histogram and mean and maximum doses of the OARs such as right lung, contralateral lung and non GTV were determined from the plans. The IMRT plans showed the superior target dose coverage, higher mean and maximum values than other VMAT techniques. PA-VMAT technique shows more lung sparing and DA-VMAT increases the V5/10/20 values of contralateral lung than other VMAT and IMRT techniques. The IMRT technique achieves highly conformal dose distribution to the target than other VMAT techniques. Comparing to the IMRT plans, the higher V5/10/20 and mean lung dose were observed in the contralateral lung in the DA-VMAT.

Purpose: The liver is the largest organ in the abdomen and is often irradiated in radiotherapy for non-hepatic malignancies. As most of the studies on changes in liver volume are on hepatocellular carcinoma based on liver dysfunction, there are few studies on healthy liver. In this study, we investigated the relationship between absorbed dose and changes in liver volume after chemoradiotherapy for esophageal cancer in patients without apparent pre-treatment liver dysfunction. Materials and methods: Liver volume was compared between pre-treatment, acute (< 4 months) and late post-treatment (≥ 4 and < 13 months) phases in 12 patients using abdominal plain CT images. Volume changes were evaluated separately for the right and left lobes. We investigated the relationship between the volume change and VxGy (percentage of volume received x Gy or more dose). In addition, volume change for each absorbed dose was investigated using deformable image registration. Results: The volume of the left lobe showed a significant decrease between pre-treatment and acute post-treatment phases (p < 0.001), while the volume of right lobe and between acute and late post-treatment phase of left lobe did not. The mean value of the volume reduction rate of the left lobe was 51.1% and equivalent to the mean value of V30Gy. As a result of the volume change for each absorbed dose, the volume reduction rate increased as the absorbed dose increased, and a significant volume loss was observed at doses above 11 Gy. Conclusion: Volume of the liver significantly decreased only in the acute phase after chemoradiotherapy for esophageal cancer. The tolerable dose for a healthy liver is generally considered to be 30 Gy, but attention should be paid to lower doses to avoid radiation-induced liver injury. [ABSTRACT FROM AUTHOR]

Background: A relationship between the axillary-lateral thoracic vessel juncture (ALTJ) dose and lymphedema rate has been reported in patients with breast cancer. The purpose of this study was to validate this relationship and explore whether incorporation of the ALTJ dose-distribution parameters improves the prediction model’s accuracy. Methods: A total of 1,449 women with breast cancer who were treated with multimodal therapies from two institutions were analyzed. We categorized regional nodal irradiation (RNI) as limited RNI, which excluded level I/II, vs extensive RNI, which included level I/II. The ALTJ was delineated retrospectively, and dosimetric and clinical parameters were analyzed to determine the accuracy of predicting the development of lymphedema. Decision tree and random forest algorithms were used to construct the prediction models of the obtained dataset. We used Harrell’s C-index to assess discrimination. Results: The median follow-up time was 77.3 months, and the 5-year lymphedema rate was 6.8 %. According to the decision tree analysis, the lowest lymphedema rate (5-year, 1.2 %) was observed in patients with ≤ six removed lymph nodes and ≤ 66 % ALTJ V35Gy. The highest lymphedema rate was observed in patients with > 15 removed lymph nodes and an ALTJ maximum dose (Dmax) of > 53 Gy (5-year, 71.4 %). Patients with > 15 removed lymph nodes and an ALTJ Dmax ≤ 53 Gy had the second highest rate (5-year, 21.5 %). All other patients had relatively minor differences, with a rate of 9.5 % at 5 years. Random forest analysis revealed that the model’s C-index increased from 0.84 to 0.90 if dosimetric parameters were included instead of RNI (P

Background: Weak correlation between gamma passing rates and dose differences in target volumes and organs at risk (OARs) has been reported in several studies. Evaluation on the differences between planned dose–volume histogram (DVH) and reconstructed DVH from measurement was adopted and incorporated into patient‐specific quality assurance (PSQA). However, it is difficult to develop a methodology allowing the evaluation of errors on DVHs accurately and quickly. Purpose: To develop a DVH‐based pretreatment PSQA for volumetric modulated arc therapy (VMAT) with combined deep learning (DL) and machine learning models to overcome the limitation of conventional gamma index (GI) and improve the efficiency of DVH‐based PSQA. Methods: A DL model with a three‐dimensional squeeze‐and‐excitation residual blocks incorporated into a modified U‐net was developed to predict the measured PSQA DVHs of 208 head‐and‐neck (H&N) cancer patients underwent VMAT between 2018 and 2021 from two hospitals, in which 162 cases was randomly selected for training, 18 for validation, and 28 for testing. After evaluating the differences between treatment planning system (TPS) and PSQA DVHs predicted by DL model with multiple metrics, a pass or fail (PoF) classification model was developed using XGBoost algorithm. Evaluation of domain experts on dose errors between TPS and reconstructed PSQA DVHs was taken as ground truth for PoF classification model training. Results: The prediction model was able to achieve a good agreement between predicted, measured, and TPS doses. Quantitative evaluation demonstrated no significant difference between predicted PSQA dose and measured dose for target and OARs, except for Dmean of PTV6900 (p = 0.001), D50 of PTV6000 (p = 0.014), D2 of PTV5400 (p = 0.009), D50 of left parotid (p = 0.015), and Dmax of left inner ear (p = 0.007). The XGBoost model achieved an area under curves, accuracy, sensitivity, and specificity of 0.89 versus 0.88, 0.89 versus 0.86, 0. 71 versus 0.71, and 0.95 versus 0.91 with measured and predicted PSQA doses, respectively. The agreement between domain experts and the classification model was 86% for 28 test cases. Conclusions: The successful prediction of PSQA doses and classification of PoF for H&N VMAT PSQA indicating that this DVH‐based PSQA method is promising to overcome the limitations of GI and to improve the efficiency and accuracy of VMAT delivery. [ABSTRACT FROM AUTHOR]

Abstract Background Post-therapy [90Y] PET/CT-based dosimetry is currently recommended to validate treatment planning as [99mTc] MAA SPECT/CT is often a poor predictor of subsequent actual [90Y] absorbed dose. Treatment planning software became available allowing 3D voxel dosimetry offering tumour-absorbed dose distributions and dose-volume histograms (DVH). We aim to assess dose–response effects in post-therapy [90Y] PET/CT dosimetry in SIRT-treated HCC patients for predicting overall and progression-free survival (OS and PFS) and four-month follow-up tumour response (mRECIST). Tumour-absorbed dose and mean percentage of the tumour volume (V) receiving ≥ 100, 150, 200, or 250 Gy and mean minimum absorbed dose (D) delivered to 30%, 50%, 70%, and 90% of tumour volume were calculated from DVH’s. Depending on the mean tumour -absorbed dose, treated lesions were assigned to a

Purpose: Development and validation of a simple and convenient computational program in MATLAB environment for estimating the tumor control probability (TCP) and the normal tissue complication probability (NTCP), as a decision support system for routine plan evaluation.Materials and Methods: We developed an in-house software using MATLAB 2016b (Mathworks) for estimating TCP and NTCP named as RBMODELV1. The program contains Niemierko free equivalent uniform dose (EUD) program code provided in authors research article. For rest of radiobiological (RB) models in the software separate coding is performed. The program accepts cumulative dose-volume histogram file in (.txt) format containing two columns dose and volume. A set of two RB parameters were prepared, default and user-dependent in excel sheet named as RBDATA. We cross-validated results of RBMODELV1 software with BioSuite software for Poisson's TCP model and Lyman-Kutcher-Burman (LKB) model. A set of total 20 patient's data of head and neck site took under study and respective TCP and NTCP calculated by all the RB models and compared.Results: This is the first study in which we tried to establish correlation between the mean doses (EUD) received by parallel structure (parotid gland and oral cavity) and predicted percentage of NTCP values. It is found that mean dose in the range of 35-40 Gy for parotid gland can result in more than 50% NTCP predicted by all four RB models. Similarly oral cavity receiving mean dose in the range of 53-58 Gy can results in more than 35% NTCP predicted by all the four models. There is <3% variation observed between TCP calculated by BioSuite and RBMODELV1 software and <4% variation observed between predicted NTCP for parotid gland and oral cavity OAR from LKB model by both the software.Conclusion: We created simple software RBMODELV1 which can be used as a research tool as well as decision support system. [ABSTRACT FROM AUTHOR]

Purpose: To investigate the dependency of dose‐volume histogram (DVH) behavior and precision on underlying discretization using shapes and dose distributions with known analytical DVHs for five commercial DVH calculators. Methods: DVHs and summary metrics were extracted from all five systems using synthetic cone and cylinder objects for which the true volume and DVH curves were known. Trends in the curves and metrics were explored by varying the underlying voxelization of the CT image, structure set, and dose grid as well by varying the geometry of the structure and direction of a linear dose gradient. Using synthetic structures allowed for comparison with ground truth DVH curves to assess their accuracy while an algorithm was additionally developed to assess the precision of each system. The precision was calculated with a novel algorithm that treats any "stair step" behavior in a DVH curve as an uncertainty band and calculates the width, characterized as a percent difference, of the band for various DVH metrics. The underlying voxelization was additionally changed and DVHs were extracted for two clinical examples. The details of how each system calculated DVHs were also investigated and tendencies in the calculated curves, metrics, and precision were related to choices made in the calculation methodology. Results: Calculation methodology differences that had a noticeable impact on the DVH curves and summary metrics include supersampling beyond the input grids and interpretation of the superior and inferior ends of the structures. Among the systems studied, the median precision ranged from 0.902% to 3.22%, and interquartile ranges varied from 1.09% to 3.91%. Conclusions: Commercial dose‐evaluation solutions can calculate different DVH curves, structure volume measures, and dose statistics for the same input data due to differences in their calculation methodologies. This study highlights the importance of understanding and investigating the DVH calculation when considering a new clinical system and when using more than one system for data transfer. [ABSTRACT FROM AUTHOR]

Background: The gamma index and dose–volume histogram (DVH)-based patient-specific quality assurance (QA) measures commonly applied in radiotherapy planning are unable to simultaneously deliver detailed locations and magnitudes of discrepancy between isodoses of planned and delivered dose distributions. By exploiting statistical classification performance measures such as sensitivity or specificity, compliance between a planned and delivered isodose may be evaluated locally, both for organs-at-risk (OAR) and the planning target volume (PTV), at any specified isodose level. Thus, a patient-specific QA tool may be developed to supplement those presently available in clinical radiotherapy. Materials and methods: A method was developed to locally establish and report dose delivery errors in three-dimensional (3D) isodoses of planned (reference) and delivered (evaluated) dose distributions simultaneously as a function the dose level and of spatial location. At any given isodose level, the total volume of delivered dose containing the reference and the evaluated isodoses is locally decomposed into four subregions: true positive—subregions within both reference and evaluated isodoses, true negative—outside of both of these isodoses, false positive—inside the evaluated isodose but not the reference isodose, and false negatives—inside the reference isodose but not the evaluated isodose. Such subregions may be established over the whole volume of delivered dose. This decomposition allows the construction of a confusion matrix and calculation of various indices to quantify the discrepancies between the selected planned and delivered isodose distributions, over the complete range of values of dose delivered. The 3D projection and visualization of the spatial distribution of these discrepancies facilitates the application of the developed method in clinical practice. Results: Several clinical photon radiotherapy plans were analyzed using the developed method. In some plans at certain isodose levels, dose delivery errors were found at anatomically significant locations. These errors were not otherwise highlighted—neither by gamma analysis nor by DVH-based QA measures. A specially developed 3D projection tool to visualize the spatial distribution of such errors against anatomical features of the patient aids in the proposed analysis of therapy plans. Conclusions: The proposed method is able to spatially locate delivery errors at selected isodose levels and may supplement the presently applied gamma analysis and DVH-based QA measures in patient-specific radiotherapy planning. [ABSTRACT FROM AUTHOR]

Purpose. To provide a novel and personalized method ( FLIP, FLow and Irradiation Personalized) using patient-specific circulating blood flows and individualized time-dependent irradiation distributions, to quantify the dose delivered to blood in large vessels during proton or photon external beam radiotherapy. Methods. Patient-specific data were obtained from ten cancer patients undergoing radiotherapy, including the blood velocity field in large vessels and the temporal irradiation scheme using photons or protons. The large vessels and the corresponding blood flow velocities are obtained from phase-contrast MRI sequences. The blood dose is obtained discretizing the fluid into individual blood particles (BPs). A Lagrangian approach was applied to simulate the BPs trajectories along the vascular velocity field flowlines. Beam delivery dynamics was obtained from beam delivery machine measurements. The whole IS is split into a sequence of successive IEs, each one with its constant dose rate, as well as its corresponding initial and final time. Calculating the dose rate and knowing the spatiotemporal distribution of BPs, the dose is computed by accumulating the energy received by each BP as the time-dependent irradiation beams take place during the treatment. Results. Blood dose volume histograms from proton therapy and photon radiotherapy patients were assessed. The irradiation times distribution is obtained for BPs in both modalities. Two dosimetric parameters are presented: (i) D 3% , representing the minimum dose received by the 3% of BPs receiving the highest doses, and (ii) V 0.5 Gy , denoting the blood volume percentage that has received at least 0.5 Gy. Conclusion. A novel methodology is proposed for quantifying the circulating blood dose along large vessels. This methodology involves the use of patient-specific vasculature, blood flow velocity field, and dose delivery dynamics recovered from the irradiation machine. Relevant parameters that affect the dose received, as the distance between large vessels and CTV, are identified., (© 2024 Institute of Physics and Engineering in Medicine. All rights, including for text and data mining, AI training, and similar technologies, are reserved.)

Background and purpose: In radiotherapy (RT) for pancreatic cancer, the pancreas is considered an important organ at risk. However, there are insufficient reports on pancreatic function deterioration after X-ray RT as organ at risk, and there are no reports on those after carbon ion (C-ion) RT. Here, we evaluated pancreatic exocrine insufficiency (PEI) after C-ion RT using dose-volume histogram (DVH) analysis. Materials and methods: Data were retrospectively collected from patients who had undergone C-ion RT for pancreatic cancer between July 2013 and June 2019. The prescribed C-ion doses were 55.2 Gy (relative biological effectiveness) in 12 fractions. Serum pancreatic amylase and lipase values were measured before and after C-ion RT. In DVH analysis, we assessed V5Gy–50Gy and V

• Resting-state fMRI detected early radiation-induced brain functional abnormalities. • Brain nodal changes were dynamic, mainly manifesting an 'impairment-recovery' pattern. • D 20cc was an important prognostic determinant for nodal changes of STG.R. To investigate radiotherapy (RT)-related brain network changes in patients with nasopharyngeal carcinoma (NPC) over time and develop least absolute shrinkage and selection operator (LASSO)-based multivariable normal tissue complication probability (NTCP) models to predict RT-related brain network changes. 36 NPC patients were followed up at four timepoints: baseline, within 3 months (acute), 6 months (subacute), and 12 months (delayed) post-RT. 15 comparable healthy controls (HCs) were finally included and followed up in parallel. Functional neuroimaging data, dose–volume parameters of bilateral temporal lobes and Montreal Cognitive Assessment (MoCA) were acquired. Graph theoretical analysis and mixed-design analysis of variance were performed to investigate how the brain global and nodal changes were affected by RT. Multivariate logistic regression NTCP models were developed. LASSO with nested cross-validation strategy was used to select features. The relationships between network changes and MoCA changes were also examined. Significant changes were detected in nodal efficiency (NE) in NPC patients but not in HCs over time. Altered NE was distributed in the bilateral frontal, temporal lobes and the right insula, which showed a "decrease-increase/recovery" pattern over time. Among all models, the model for predicting NE changes of STG.R showed a relatively good performance (area under the receiver operating curve: 0.68), and D 20cc and V 20 to right temporal lobe outperformed in this model. Our findings indicate that RT-induced brain injury begin at the acute period and follow a recovery over time. Furthermore, our study presents prediction models for brain dysfunction based on the dosimetric and clinical parameters. [ABSTRACT FROM AUTHOR]

Objectives: To estimate appropriate dose-volume parameters for avoidance of pneumonitis in use of chemoradiotherapy and durvalumab for treatment of lung cancer. Materials and methods: Patients with non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab at 9 centers were enrolled in the study. Three-dimensional radiotherapy, intensity modulated radiotherapy, and proton beam therapy were used. The frequency and severity of pneumonitis and the dose-volume relationship for normal lung were evaluated. Univariable and multivariable analyses were conducted to identify risk factors. A covariate adjusted hazard ratio was then estimated for the percentages of normal lung volume irradiated at ≥ X Gy (Vx) (X = 5–40) and lung volume non-irradiated at ≥ X Gy (X = 5–40), with the covariates selected in the variable selection. Cumulative incidence functions and covariate adjusted hazard ratios were also estimated for dichotomized variables, with estimated cut-off points. Results: A total of 91 patients were enrolled in the study. The median time from the start of radiotherapy to development of pneumonitis was 4.1 months. Pneumonitis was observed in 80 patients (88%), including grade 2 or severe pneumonitis in 31 (34%) and ≥ grade 3 pneumonitis in 11 (12%). Pneumonitis was inside the irradiation field in 73 of the 80 patients (91%). The selected factors for ≥ grade 2 pneumonitis were V20, and primary site (upper lobe) in multivariable analysis. The cut off value of V20 was 18.99%, and there was a significant difference between V20 of

Background: Tooth loss reduces quality of life; however, little is known about tooth loss caused by carbon ion radiotherapy (CIRT). Here, we aimed to elucidate the incidence of tooth loss post-CIRT for head and neck tumors and to identify risk-predictive dosimetric parameters. Methods: This study enrolled 14 patients (i.e., 171 teeth in total) with head and neck non-squamous cell carcinoma. All patients received CIRT comprised of 57.6 or 64.0 Gy (relative biological effectiveness, RBE) in 16 fractions. Dose–volume analysis of the teeth was performed using receiver operating characteristic (ROC) curve analysis with VX (i.e., the volume irradiated with X Gy (RBE)). Results: The median follow-up period was 69.1 months. The median time of tooth loss was 38.6 months. The 5 year cumulative incidence of tooth loss was 13.3%. The volume of irradiated teeth was significantly greater for the lost teeth than for the remaining teeth throughout the dose range. Using the cut-offs calculated from ROC curve analysis, V30–V60 showed high accuracy (i.e., >94%) for predicting tooth loss, with V50 being the most accurate (cut-off, 58.1%; accuracy, 0.95). Conclusions: This is the first report to examine the incidence of tooth loss post-CIRT and to identify risk-predictive dosimetric parameters.

Dose conformity is an essential parameter used in radiotherapy and radiosurgery that measures the correspondence of the dose distribution derived from a Treatment Planning System (TPS) with the actual volume to be treated, the Planning Treatment Volume (PTV). The present work uses a method based on the expansion of dose distributions and PTVs by three-dimensional Zernike polynomials and further comparison of their moments to define a general criterion of dose conformity. To carry on this study, data coming from 20 patients comprising 80 datasets exported from the TPS, which included imaging data (PTVs) and dose distributions corresponding to different treatment modalities: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT), were used. The expansions in Zernike polynomials were obtained up to order 6 and reconstructed dose distributions and PTVs were obtained and compared, and several definitions for a general dose conformity index were proposed. Results indicate agreement between the proposed dose conformity index and the Conformation Number CN. The proposed method allows for a systematic approach to the analysis of dose distributions with further extensions in AI applications. • 3D Zernike expansions for radiotherapy PTVs are proposed to assess dose conformity. • Zernike moments comparison can be used to define a general dose conformity index. • Possible outcomes could be translated directly to TPS, improving dose conformity. • Results could provide elements for AI implementation in radiotherapy planning. [ABSTRACT FROM AUTHOR]

Introduction: Although the primary treatment option for hilar cholangiocarcinoma (HC) has been surgical resection, most patients present with unresectable advanced tumors at the time of diagnosis. Particle therapy (PT) holds great potential for HC, even though the anatomical proximity to the gastrointestinal tract prevents delivering a radical dose to the tumor. Space-making PT (SMPT), consisting of spacer placement surgery and subsequent PT, has been developed to minimize complications and maximize the therapeutic benefit of dose escalation for HC. This study aimed to conduct a dosimetric evaluation and examine the effectiveness of SMPT for the treatment of HC. Methods: Between 2007 and 2018, 12 patients with unresectable HC treated with SMPT were enrolled. The treatment outcomes and effectiveness of spacer placement surgery were evaluated through analyses of pre- and post-surgical parameters of dose-volume histograms. Results: All patients completed the planned SMPT protocol. The median survival time was 29.6 months, and the 1- and 3-year overall survival rates were 82.5% and 45.8%, respectively. The mean V95% value (volume irradiated with 95% of the planned treatment dose) of the gross tumor volume and clinical target volume after spacer placement surgery improved to 98.5% and 96.6% from preoperative values of 85.6% and 78.1%, respectively (p = 0.0196 and p = 0.0053, respectively). Grade 3 or higher adverse events after SMPT were seen in 6 patients. Discussion/Conclusion: SMPT led to improvements in dosimetric parameters and showed good feasibility and excellent outcomes. SMPT can be a promising novel alternative for unresectable HC. [ABSTRACT FROM AUTHOR]

Introduction: Brachytherapy always remains a keystone in the treatment of gynecological carcinoma for both definitive and adjuvant treatments. Due to the rapid fall-off nature of brachytherapy, the target gets a high dose with a low dose to the normal organs nearby and thereby increasing the tumor control probability. Aims and Objectives: This study aims at the evaluation of local control and toxicities in the carcinoma of the cervix using tandem and cylinder as brachytherapy applicator. Materials and Methods: The study was conducted between January 2014 and December 2018 in a tertiary care hospital. Thirty-one patients who fulfilled our set criterion of Clinical stage IB3–IVA, Performance status Eastern Cooperative Oncology Group 0–2 were selected. All patients were treated initially with external beam radiotherapy and later by high dose rate intracavitary brachytherapy after completion of external beam radiation therapy (EBRT). A dose of 18–21 Gy was delivered to the residual disease in three sessions with a 1-week interval between each session. The dose was optimized in such a way that the organs at risk (OAR), namely bladder and rectum received doses within their tolerance levels. The patients were continuously monitored using Common Terminology Criteria for Adverse Events version 5.0 for both acute and late toxicities and by imaging for local control. Statistical analysis using SPSS Version 20.0 (SPSS Inc., Chicago, Illinois, USA) was used to evaluate the results. Continuous variables were expressed as mean ± standard deviation, and categorical variables were summarized as frequencies and percentages. Results: Out of the 31 patients, 5 (16.1%) experienced radiation-induced Grade 1 skin changes which were due to EBRT, 1 (3.2%) had Grade 1 G. I. T toxicity, 1 (3.2%) had Grade 1 radiation-induced vaginal mucositis after brachytherapy. At 6–8-week follow-up, all the patients showed no evidence of disease on radiological imaging. At 3 months of follow-up, 1 (3.2%) patient had radiation-induced proctitis of Grades 2 and 3 (9.7%) had radiation-induced cystitis of Grades 1 and 1 (3.2%) had Grade 2 cystitis. At 6 months of follow-up, 1 (3.2%) had Grade 1, 1 (3.2%) had Grade 2, and 1 (3.2%) had Grade 3 radiation-induced proctitis. At 3 months of follow-up, 29 (93.5%) patients had no evidence of disease, while 2 (6.5%) were having residual disease on imaging. At 6 months of follow-up, all the patients were disease-free. At 12 months of follow-up, 26 (83.9%) patients were disease-free, 1 (3.2%) had local recurrence, 2 (6.5%) had distant metastasis, and 2 (6.5%) had expired. At 24 months of follow-up, 26 patients were disease-free. Acute and late toxicities were similar to those used in the treatment of carcinoma cervix by standard brachytherapy applicators. Local control was achieved in 83.87% of cases. Two-year survival was 93.5%. Conclusion: We observed that the tandem and cylinder applicator is an acceptable applicator to be used for intracavitary brachytherapy. It is safe and simple besides this; the toxicities and local control are similar to the other standard applicators used in brachytherapy in carcinoma cervix. However, the required dose prescription to point A was not possible in all the patients due to limitations of OARs. Furthermore, long-term follow-up is needed to see the patterns of failure, recurrence-free survival, overall survival, and long-term toxicities in the treated patients. [ABSTRACT FROM AUTHOR]

We investigated differences in the volumetric-modulated arc therapy (VMAT) dose distribution in prostate cancer patients treated by rectal gas removal and/or adaptive replanning. Cone-beam computed tomography (CBCT) scans were performed daily for 22 treatments in eight prostate cancer patients with excessive rectal gas, and the CBCT images were analyzed. Rectal gas removal was performed, and irradiation was delivered after prostate matching. We compared dose-volume histograms for the daily CBCT images before and after rectal gas removal. Plan A was the original plan on CBCT images before rectal gas removal. Plan B was a single reoptimized plan on CBCT images before rectal gas removal. Plan C was the original plan on CBCT images after rectal gas removal. Plan D was a single reoptimized plan on CBCT images after rectal gas removal. D 95 of the planning target volume (PTV) minus the rectum of Plan C (94.7% ± 6.6%) was significantly higher than that of Plan A (88.5% ± 10.4%). All dosimetric parameters of Plan C were improved by rectal gas removal compared with Plan A, regardless of the initial rectal gas volume. Dosimetric parameters of PTV minus the rectum of Plan B were significantly improved compared with Plan C. Additionally, the V 78 of the rectal wall of Plan B (0.2% ± 0.5%) was significantly improved compared with Plan C (3.9% ± 6.3%, p = 0.003). The dosimetric parameters of Plan D were not significantly different from Plan B. The dose distribution of prostate VMAT was improved by rectal gas removal and/or adaptive replanning. An adaptive replanning on daily CBCT images might be a better method than rectal gas removal for prostate cancer patients with excessive rectal gas. [ABSTRACT FROM AUTHOR]

Abstract Background To evaluate factors associated with osteoradionecrosis of the jaw (ORNJ) in patients with head and neck squamous cell carcinoma (HNSCC), focusing on jaw-related dose–volume histogram (DVH) parameters. Methods We retrospectively reviewed the medical records of 616 patients with HNSCC treated with curative-intent or postoperative radiation therapy (RT) during 2008–2018. Patient-related (age, sex, history of smoking or alcohol use, diabetes mellitus, performance status, pre-RT dental evaluation, pre- or post-RT tooth extraction), tumor-related (primary tumor site, T-stage, nodal status), and treatment-related (pre-RT surgery, pre-RT mandible surgery, induction or concurrent chemotherapy, RT technique) variables and DVH parameters (relative volumes of the jaw exposed to doses of 10 Gy–70 Gy [V10–70]) were investigated and compared between patients with and without ORNJ. The Mann–Whitney U test was used to compare RT dose parameters. Univariate and multivariate Cox regression analyses were used to assess factors associated with ORNJ development. Kaplan–Meier analyses were performed for cumulative ORNJ incidence estimation. Results Forty-six patients (7.5%) developed ORNJ. The median follow-up duration was 40 (range 3–145) months. The median time to ORNJ development was 27 (range 2–127) months. DVH analysis revealed that V30–V70 values were significantly higher in patients with than in those without ORNJ. In univariate analyses, primary tumor site, pre-RT mandible surgery, post-RT tooth extraction, and V60 > 14% were identified as important factors. In multivariate analyses, V60 > 14% (p = 0.0065) and primary tumor site (p = 0.0059) remained significant. The 3-year cumulative ORNJ incidence rates were 2.5% and 8.6% in patients with V60 ≤ 14% and > 14%, respectively (p 14% and oropharyngeal or oral cancer were found to be independent risk factors for ORNJ. These findings might be useful to minimize ORNJ incidence in HNSCC treated with curative RT.

Background: Post-therapy [90Y] PET/CT-based dosimetry is currently recommended to validate treatment planning as [99mTc] MAA SPECT/CT is often a poor predictor of subsequent actual [90Y] absorbed dose. Treatment planning software became available allowing 3D voxel dosimetry offering tumour-absorbed dose distributions and dose-volume histograms (DVH). We aim to assess dose–response effects in post-therapy [90Y] PET/CT dosimetry in SIRT-treated HCC patients for predicting overall and progression-free survival (OS and PFS) and four-month follow-up tumour response (mRECIST). Tumour-absorbed dose and mean percentage of the tumour volume (V) receiving ≥ 100, 150, 200, or 250 Gy and mean minimum absorbed dose (D) delivered to 30%, 50%, 70%, and 90% of tumour volume were calculated from DVH's. Depending on the mean tumour -absorbed dose, treated lesions were assigned to a < 120 Gy or ≥ 120 Gy group. Results: Thirty patients received 36 SIRT treatments, totalling 43 lesions. Median tumour-absorbed dose was significantly different between the ≥ 120 Gy (n = 28, 207 Gy, IQR 154–311 Gy) and < 120 Gy group (n = 15, 62 Gy, IQR 49–97 Gy, p <0.01). Disease control (DC) was found more frequently in the ≥ 120 Gy group (79%) compared to < 120 Gy (53%). Mean tumour-absorbed dose optimal cut-off predicting DC was 131 Gy. Tumour control probability was 54% (95% CI 52–54%) for a mean tumour-absorbed dose of 120 Gy and 90% (95% CI 87–92%) for 284 Gy. Only D30 was significantly different between DC and progressive disease (p = 0.04). For the ≥ 120 Gy group, median OS and PFS were longer (median OS 33 months, [range 8–33 months] and median PFS 23 months [range 4–33 months]) than the < 120 Gy group (median OS 17 months, [range 5–33 months] and median PFS 13 months [range 1–33 months]) (p < 0.01 and p = 0.03, respectively). Conclusions: Higher 3D voxel-based tumour-absorbed dose in patients with HCC is associated with four-month DC and longer OS and PFS. DVHs in [90Y] SIRT could play a role in evaluative dosimetry. [ABSTRACT FROM AUTHOR]

Abstract Background Radiation pneumonitis (RP) is a major pulmonary adverse event of chest radiotherapy. The PACIFIC trial that identified durvalumab as an effective subsequent‐line therapy after concurrent chemoradiotherapy (CCRT) found that patients with grade 2 or higher RP may have to be excluded from treatment under certain criteria. The purpose of this study was to investigate the relationship between grade ≥2 RP and the parameters of dose‐volume histograms after CCRT with cisplatin/docetaxel for stage III non‐small cell lung cancer and conduct a subset analysis of severe RP that can lead to the permanent discontinuation of treatment per the PACIFIC trial criteria to help determine treatment strategy. Methods We calculated the percentage of the lung volume received at least 5 Gy (V5) and 20 Gy (V20), the mean lung dose (MLD), and the lung volume spared from a 5 Gy dose (VS5) to the total lung volume. Factors affecting the incidence of grade ≥2 RP were identified; severe RP was defined as grade ≥3 as well as grade 2 RP that required ≥10 mg prednisolone for at least 12 weeks. Results This study included 45 patients. On univariate analysis, all parameters and total lung volume were found to be significant predictors of grade ≥2 RP (P = .001, .003, .03, .004, and .02, respectively). On multivariate analysis, V20 was a significant predictive factor of grade ≥2 RP (P = .007). Severe RP developed in 6 of 37 patients (16.2%) whose V20 values were 35% or lower. On univariate analysis, only V20 was a significant predictor of severe RP in these patients (P = .01). Conclusions The best approach to reduce the rate of grade ≥2 RP is to maintain the V5, V20, MLD, and VS5 as low as possible during radiotherapy planning in patients receiving definitive CCRT with cisplatin/docetaxel.

Abstract Introduction Esophagitis influences quality of life and might cause treatment interruption and hospitalization. Previous studies of risk factors focused on curative treatment for non-small cell lung cancer (NSCLC), which often involves concomitant chemoradiation (CRT). Given the uncertainty around extrapolation of dose constraints, we analyzed risk factors in patients treated with hypofractionated palliative regimens. Patients and methods A retrospective review of 106 patients treated with palliative radiotherapy or CRT between 2009 and 2017 was performed. Inclusion criteria: prescribed total dose 30–54 Gy, dose per fraction 2.5–4 Gy, esophageal dose > 1 Gy. Uni- and multivariate analyses were performed in 97 eligible patients to identify predictive factors for acute esophagitis grade ≥ 1 (CTCAE 5.0). Results Forty percent of patients were treated with 15 fractions of 2.8 Gy (42 Gy) and 28% also received chemotherapy according to the CONRAD study regimen (induction and concomitant Carboplatin/Vinorelbine) published by the Norwegian Lung Cancer Group. Thirty-four percent were treated with 10 fractions of 3 Gy. Stage IV NSCLC was present in 47%. Esophagus Dmax was 39 Gy (population median) and Dmean 15 Gy. Overall 31% of patients developed esophagitis (26% grade 2–3, no grade 4–5). Several dosimetric parameters correlated with the risk of esophagitis (Dmax, Dmean, D5cc, V20, V30, V35, V40). Dmax outperformed other dosimetric variables in multivariate analysis. Furthermore, concomitant chemotherapy significantly increased the risk of esophagitis, while oral steroid medication reduced it. In patients with Dmax ≥40 Gy a reduced Dmean (≤20 Gy) was beneficial. Conclusion In order to reduce esophagitis after hypofractionated palliative treatment lower doses than those recommended in curative NSCLC settings are preferable. Besides esophageal dose, CRT is the main risk factor for esophagitis. Additional work is needed to confirm that steroids are able to modify the risk (or to rule out confounding effects of baseline variables not included in our database).

Purpose: Brachytherapy is a major tool for dose escalation in gynecological cancer treatment. Control of rectal repletion is particularly challenging; it can impact dose received by this organ at risk and there are reported toxicities. The use of methods, such as enema and bowel preparation, to reduce rectal volume is a difficult process for patients, and its repeatability requires patients' cooperation. Due to the effect of antibiotics on reducing intestinal gases, this study was conducted to measure the effect of adding rifaximin to bowel preparation on rectal dose-volume histogram (DVH) parameters. Material and methods: In this prospective interventional study, 24 patients with cervical and endometrial cancer were treated with adjuvant high-dose-rate (HDR) brachytherapy. Both first and second sessions of brachytherapy were performed with bowel preparation, before and after the administration of rifaximin, respectively. The rectum was contoured as an organ at risk, and DVH parameters were recorded and compared in both sessions using magnetic resonance imaging (MRI)-based 3D treatment planning system. Results: Rifaximin consumption reduced the rectal volume (p = 0.01), but had no significant correlation with other DVH parameters, especially D2cc (p = 0.599). Moreover, rectal volume had no significant correlation with DVH parameters (all p-values ≤ 0.05). Conclusions: Even though the addition of rifaximin to bowel preparation significantly reduced rectal volume, no significant difference was observed in DVH parameters. Therefore, it is recommended that adjuvant vaginal cuff HDR brachytherapy should be performed without the use of rifaximin, until further researches' validate its effects. [ABSTRACT FROM AUTHOR]

The purpose of this study is to investigate the incidence of rectal toxicity and to identify the associated dosimetric predictive parameters after I-125 seed low-dose-rate brachytherapy (LDR-BT) combined with volumetric modulated arc therapy (VMAT) and dose constraints. In total, 110 patients with high-risk prostate cancer received 110 Gy LDR-BT, followed by 45 Gy VMAT. Rectal toxicity was recorded according to Common Terminology Criteria for Adverse Events v.4.03. The dosimetric factors associated with LDR-BT and VMAT were analyzed to determine their relationship with rectal toxicity. Receiver operating characteristic (ROC) curve analysis was performed for ≥ grade 2 (G2) rectal toxicity prediction. The follow-up duration was 10.1–115.2 months (median 60.5 months). Seven patients had G2 rectal hemorrhage, and none of the patients had grade 3 rectal hemorrhage. In the univariate analysis, the rectal volume receiving 100% of the prescribed dose (rV 100) (p < 0.001), the dose covering 2 cc of the rectum (rD 2cc) during LDR-BT (p = 0.002), and the combined rD 2cc during LDR-BT and VMAT (p = 0.001) were identified as predictors of G2 rectal hemorrhage. In the ROC curve analysis, the cutoff value was 0.46 cc for rV 100 , 74.0 Gy for rD 2cc , and 86.8 GyEQD 2 for combined rD 2cc. Predictors of late ≥ G2 rectal hemorrhage are rV 100 , rD 2cc , and combined rD 2cc. The incidence of rectal toxicity is low and acceptable in this setting and is highly dependent on the rectal dose of LDR-BT. The use of higher-quality LDR-BT and VMAT dose constraints may further reduce the rate of rectal hemorrhage. [ABSTRACT FROM AUTHOR]

• PIF following C-ion RT for uterus carcinomas were retrospectively evaluated. • The 5-year cumulative PIF incidence in the whole pelvis was 42.4%. • The 5-year cumulative PIF incidence in the sacrum was 27.1%. • V10–40, D 50% , D mean , BMI, smoking, and port directions may affect sacral PIF. There is growing evidence on the role of carbon-ion radiotherapy (C-ion RT) for gynaecological tumours. Pelvic insufficiency fracture (PIF) decreases the quality of life after photon beam radiotherapy (RT). However, there is little information on PIF after C-ion RT. This study retrospectively assessed incidence of PIF after C-ion RT for uterine carcinomas (UCs) and the associations of clinical and dosimetric parameters with PIF incidence. We performed a pooled analysis of 102 patients with UCs who underwent definitive C-ion RT alone and were followed up for >6 months without any additional RT in the pelvic region. PIF occurrence was surveyed using magnetic resonance imaging and/or computed tomography. Associations of clinical and dosimetric parameters with PIF incidence were analysed. The 2- and 5-year actuarial incidences of ≥grade 1 PIF in all pelvic regions were 22.3% and 42.4%, respectively. The most frequent site of involvement was the sacrum. Log-rank tests showed that higher volumes receiving >10 Gy (relative biological effectiveness) (V10), V20, V30, and V40, body mass index (BMI) under 18.5, and current smoking were associated with increased incidence of ≥grade 1 PIF in the sacrum. We clarified the actuarial incidence of PIF after C-ion RT for UCs. Higher V10, V20, V30, V40, D 50% , D mean , current smoking, BMI <18.5, and using the anterior-posterior direction in whole pelvic irradiation were associated with higher incidences of PIF in the sacrum. The present results may lead to further improvement of C-ion RT for UCs. [ABSTRACT FROM AUTHOR]

Background: To evaluate factors associated with osteoradionecrosis of the jaw (ORNJ) in patients with head and neck squamous cell carcinoma (HNSCC), focusing on jaw-related dose-volume histogram (DVH) parameters.Methods: We retrospectively reviewed the medical records of 616 patients with HNSCC treated with curative-intent or postoperative radiation therapy (RT) during 2008-2018. Patient-related (age, sex, history of smoking or alcohol use, diabetes mellitus, performance status, pre-RT dental evaluation, pre- or post-RT tooth extraction), tumor-related (primary tumor site, T-stage, nodal status), and treatment-related (pre-RT surgery, pre-RT mandible surgery, induction or concurrent chemotherapy, RT technique) variables and DVH parameters (relative volumes of the jaw exposed to doses of 10 Gy-70 Gy [V10-70]) were investigated and compared between patients with and without ORNJ. The Mann-Whitney U test was used to compare RT dose parameters. Univariate and multivariate Cox regression analyses were used to assess factors associated with ORNJ development. Kaplan-Meier analyses were performed for cumulative ORNJ incidence estimation.Results: Forty-six patients (7.5%) developed ORNJ. The median follow-up duration was 40 (range 3-145) months. The median time to ORNJ development was 27 (range 2-127) months. DVH analysis revealed that V30-V70 values were significantly higher in patients with than in those without ORNJ. In univariate analyses, primary tumor site, pre-RT mandible surgery, post-RT tooth extraction, and V60 > 14% were identified as important factors. In multivariate analyses, V60 > 14% (p = 0.0065) and primary tumor site (p = 0.0059) remained significant. The 3-year cumulative ORNJ incidence rates were 2.5% and 8.6% in patients with V60 ≤ 14% and > 14%, respectively (p < 0.0001), and 9.3% and 1.4% in patients with oropharyngeal or oral cancer and other cancers, respectively (p < 0.0001).Conclusions: V60 > 14% and oropharyngeal or oral cancer were found to be independent risk factors for ORNJ. These findings might be useful to minimize ORNJ incidence in HNSCC treated with curative RT. [ABSTRACT FROM AUTHOR]

Purpose: This study investigated the suitability of brachytherapy technique selection based on pre-brachytherapy magnetic resonance imaging (MRI) findings in cervical cancer by evaluating dose-volume histogram parameters. Material and methods: We retrospectively evaluated data from 61 patients with cervical cancer who underwent pre-brachytherapy MRI within 7 days before their first high-dose-rate brachytherapy treatment, selected according to pre-brachytherapy MRI findings. Combined intracavitary brachytherapy with interstitial techniques (IC/ISBT) or interstitial brachytherapy (ISBT) were favored treatments for poor-responding tumors after concurrent chemoradiotherapy, asymmetrical tumors, bulky parametrial extensions, bulky primary disease, and extensive paravaginal or distal vaginal involvement. Intracavitary brachytherapy (ICBT) was the preferred treatment for small tumors without extensive involvement of the vagina and parametrium. Results: The median tumor size was 58 mm on pre-treatment MRI and 38 mm on pre-brachytherapy MRI. On pre-brachytherapy MRI, 13 patients had a tumor with severe vaginal invasion, 15 patients presented with an asymmetrical bulky tumor, and 4 patients had bulky residual tumors. IC/ISBT or ISBT were administered to 26 patients (43%). Median equivalent dose in 2 Gy fractions of clinical target volume D90 was 70.8 Gy for all patients. Median clinical target volume D90 in each brachytherapy session exceeded the prescribed dose in both patients treated with ICBT and IC/ISBT or ISBT. Median equivalent dose in 2 Gy fractions of D2cc to the bladder, sigmoid colon, and rectum was 69.5, 52.0, and 58.4 Gy, respectively. All cases remained within the doses recommended for organs at risk. Conclusions: Pre-brachytherapy MRI may be helpful in selecting suitable candidates for each type of brachytherapy and deliver the recommended doses to the tumor and organs at risk, particularly in cases with large tumors, poor response to concurrent chemoradiotherapy, asymmetrical tumors, severe vaginal invasion, extensive parametrial invasion, and/or corpus invasion. [ABSTRACT FROM AUTHOR]

Craniospinal irradiation (CSI) is a complex radiation therapy technique that is used for patients, often children and teenagers/young adults, with tumors that have a propensity to spread throughout the central nervous system such as medulloblastoma. CSI is associated with important long‐term side effects, the risk of which may be affected by numerous factors including radiation modality and technique. Lack of standardization for a technique that is used even in larger radiation oncology departments only a few times each year may be one such factor and the current ad hoc manner of planning new CSI patients may be greatly improved by implementing a dose–volume histogram registry (DVHR) to use previous patient data to facilitate prospective constraint guidance for organs at risk. In this work, we implemented a DVHR and used it to provide standardized constraints for CSI planning. Mann–Whitney U tests and mean differences at 95% confidence intervals were used to compare two cohorts (pre‐ and post‐DVHR intervention) at specific dosimetric points to determine if observed improvements in standardization were statistically significant. Through this approach, we have shown that the implementation of dosimetric constraints based on DVHR‐derived data helped improve the standardization of pediatric CSI planning at our center. The DVHR also provided guidance for a change in CSI technique, helping to achieve practice standardization across TomoTherapy and IMRT. [ABSTRACT FROM AUTHOR]

Voxelizing three-dimensional surfaces into binary image volumes is a frequently performed operation in medical applications. In radiation therapy (RT), dose-volume histograms (DVHs) calculated within such surfaces are used to assess the quality of an RT treatment plan in both clinical and research settings. To calculate a DVH, the 3D surfaces need to be voxelized into binary volumes. The voxelization parameters may considerably influence the output DVH. An effective way to improve the quality of the voxelized volume (i.e., increasing similarity between that and the original structure) is to apply oversampling to increase the resolution of the output binary volume. However, increasing the oversampling factor raises computational and storage demand. This paper introduces a fuzzy inference system that determines an optimal oversampling factor based on relative structure size and complexity, finding the balance between voxelization accuracy and computation time. The proposed algorithm was used to automatically calculate oversampling factor in four RT studies: two phantoms and two real patients. The results show that the method is able to find the optimal oversampling factor in most cases, and the calculated DVHs show good match to those calculated using manual overall oversampling of two. The algorithm can potentially be adopted by RT treatment planning systems based on the open-source implementation to maintain high DVH quality, enabling the planning system to find the optimal treatment plan faster and more reliably. [ABSTRACT FROM AUTHOR]

Objective: To analyze the difference between planned dose and delivered dose by accumulating the dose based on CT and CBCT image deformable registration.Methods: The clinical data of 24 NSCLC (non-small cell lung cancer) patients receiving conformal radiotherapy or intensity-modulated radiotherapy (IMRT) were retrospectively analyzed. With the CBCT image of each week as the target image, we performed the deformation registration for CBCT images and planning CT images in RayStation. The delivered dose of CBCT images compared to the planning CT images was accumulated with the use of mapping relationships in registration. The differences in planned dose and accumulative dose of target and at-risk organs were compared.Results: The average planned and accumulative doses of GTV in 24 patients were 5832.45 ± 645.42 and 5750.65 ± 630.27 cGy, respectively (P < 0.05). The average planning target volume (PTV) in CT plans and accumulation plans reaching the prescription dose was 95.59 and 81.47% of the PTV (P > 0.05). At the stage of treatment, the volumes of the at-risk organs in CBCT images were not significantly different. There were no statistically significant differences in the probability of complications in the right lung, left lung, heart, total lung, or spinal cord (P > 0.05).Conclusion: With the dose deformable registration method, the dose caused by changes in the target anatomical structure of NSCLC patients was found. The dose to organs did not change much. However, in some patients, the received radiation in the target organ was less than the prescribed dose.

Abstract Background Carbon-ion radiotherapy (C-ion RT) provides better dose distribution in cancer treatment compared to photons. Additionally, carbon-ion beams provide a higher biological effectiveness, and thus a higher tumor control probability. However, information regarding the dose constraints for organs at risk in C-ion RT is limited. This study aimed to determine the predictive factors for late morbidities in the rectum and bladder after carbon-ion C-ion RT for uterus carcinomas. Methods Between June 1995 and January 2010, 134 patients with uterus carcinomas were treated with C-ion RT with curative intent; prescription doses of 52.8–74.4 Gy (relative biological effectiveness) were delivered in 20–24 fractions. Of these patients, 132 who were followed up for > 6 months were analyzed. We separated the data in two subgroups, a 24 fractions group and a 20 fractions group. Late morbidities, proctitis, and cystitis were assessed according to the Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer criteria. The correlations of clinical and dosimetric parameters, V10–V60, D5cc, D2cc, and Dmax, with the incidence of ≥grade 1 morbidities were retrospectively analyzed. Results In the 24 fractions group, the 3-year actuarial occurrence rates of ≥grade 1 rectal and bladder morbidities were 64 and 9%, respectively. In addition, in the 20 fractions group, the 3-year actuarial occurrence rates of ≥grade 1 rectal and bladder morbidities were 32 and 19%, respectively. Regarding the dose–volume histogram data on the rectum, the D5cc and D2cc were significantly higher in patients with ≥grade 1 proctitis than in those without morbidity. In addition, the D5cc for the bladder was significantly higher in patients with ≥grade 1 cystitis than in those without morbidity. Results of univariate analyses showed that D2cc of the rectum was correlated with the development of ≥grade 1 late proctitis. Moreover, D5cc of the bladder was correlated with the development of ≥grade 1 late cystitis. Conclusions The present study identified the dose–volume relationships in C-ion RT regarding the occurrence of late morbidities in the rectum and bladder. Assessment of the factors discussed herein would be beneficial in preventing late morbidities after C-ion RT for pelvic malignancies. Trial registration Retrospectively registered (NIRS: 16–040).

The aim of this study is to compare the physical wedge (PW) with enhanced dynamic wedge (EDW) to determine the difference in the dose distribution affecting the treated breast and the contralateral breast, lungs, heart, esophagus, spine, and surrounding skin in the radiotherapy of breast cancer. Computed tomography (CT) data sets of 30 breast cancer patients were selected from the database for the study. The treatment plans which were executed with PW were re-planned with EDW without changing the beam parameters. Keeping the wedge angles same, the analytic anisotropic algorithm (AAA) with heterogeneity correction was used for dose calculation in all plans. The prescription was 50 Gy in 25 fractions. The dose- volume histogram (DVH) of the planning target volume (PTV) and critical structures of both PW and EDW plans were analyzed. The analysis showed that the maximum dose within the target volume is higher in EDW plan compared to PW plan. However the PTV conformity index (CI) remained the same in both plans. For all the critical structures, the EDW technique offered less dose compared to PW technique. The effect of volume of the contralateral breast on the dose to contralateral breast and the effect of volume of PTV breast for patients with carcinoma left breast on the dose to heart were studied and analyzed for the two wedges. No correlation between volumes and dose parameters was found for the two techniques. The number of monitor units to deliver a particular dose with EDW field is less than that of PW field due to change in wedge factor. As EDW produces less scattered dose to structures outside the treatment field, the risk of a second malignancy can be reduced with this technique.

Introduction: This study evaluates treatment plans aiming at determining the expected impact of daily patient setup corrections on the delivered dose distribution and plan parameters in head-and-neck radiotherapy. Materials and Methods: In this study, 10 head-and-neck cancer patients are evaluated. For the evaluation of daily changes of the patient internal anatomy, image-guided radiation therapy based on computed tomography (CT)-on-rails was used. The daily-acquired CT-on-rails images were deformedly registered to the CT scan that was used during treatment planning. Two approaches were used during data analysis (“cascade” and “one-to-all”). The dosimetric and radiobiological differences of the dose distributions with and without patient setup correction were calculated. The evaluation is performed using dose–volume histograms; the biologically effective uniform dose ([INSIDE:1]) and the complication-free tumor control probability (P+) were also calculated. The dose–response curves of each target and organ at risk (OAR), as well as the corresponding P+ curves, were calculated. Results: The average difference for the “one-to-all” case is 0.6 ± 1.8 Gy and for the “cascade” case is 0.5 ± 1.8 Gy. The value of P+ was lowest for the cascade case (in 80% of the patients). Discussion: Overall, the lowest PIis observed in the one-to-all cases. Dosimetrically, CT-on-rails data are not worse or better than the planned data. Conclusions: The differences between the evaluated “one-to-all” and “cascade” dose distributions were small. Although the differences of those doses against the “planned” dose distributions were small for the majority of the patients, they were large for given patients at risk and OAR.

Objectives: To compare the dose evaluation parameters between conventional (using loose seed alone) and hybrid (using loose seeds in combination with stranded seeds) low-dose rate brachytherapy for prostate cancer. Methods: Between 2014 and July 2016, a total of 219 patients who underwent lowdose rate brachytherapy were enrolled in a randomized controlled trial (trial number: UMIN 000012780). Patients were randomized and allocated to two groups (conventional method vs hybrid method). Post-dosimetric parameters (%D90, minimal percentage of the dose received by 90% of the prostate gland; V100, percentage of the prostate volume receiving 100% of the prescribed minimal peripheral dose; V150, percentage of the prostate volume receiving 150% of the prescribed minimal peripheral dose; %UD30, minimal percentage of the dose received by 30% of the urethra; R100, rectal volume [mL] receiving 100% of the prescribed dose) calculated at 1 month after seed implantation by computed tomography scan were compared between the two groups, as well as the post-dosimetric parameters using the planning target volume of the prostate + 5-mm margin. Results: Regarding dose evaluation parameters, the prostate dose (%D90, V100, V150) and the urethral dose (%UD30) were not significantly different between the two groups, whereas V100 (+5-mm margin) and %D90 (+5-mm margin) were significantly higher in the hybrid method group compared with the conventional method group (P < 0.001). Conclusion: The present randomized study shows that the hybrid method of low-dose rate brachytherapy can achieve a higher coverage of the periprostatic region compared with the conventional method while maintaining an acceptable level of urethral and rectal doses. [ABSTRACT FROM AUTHOR]

Purpose: To develop a deep learning‐based model to predict achievable dose–volume histograms (DVHs) of organs at risk (OARs) for automation of inverse planning. Methods: The model was based on a connected residual deconvolution network (CResDevNet) and compared with UNet as a baseline. The DVHs of OARs are dependent on patient anatomical features of the planning target volumes and OARs, and these spatial relationships can be learned automatically from prior high‐quality plans. The contours of planning target volumes and OARs were parsed from the plan database and used as the input to the model, and the dose–area histograms (DAHs) of the OARs were output from the model. The model was trained from scratch by correlating anatomical features with DAHs of OARs, then accumulating these histograms to obtain the final predicted DVH for each OAR. Helical tomotherapy plans for 170 nasopharyngeal cancer patients were used to train and validate the model. An additional 60 patient treatment plans were used to test the predictive accuracy of the model. The DVHs and dose–volume indices (DVIs) of clinical interest for each OAR in the testing dataset were predicted to evaluate the accuracy of the models. The mean absolute errors in the DVIs for each OAR were calculated using each model and statistically compared using a paired‐samples t‐test. Dice similarity coefficients for areas of the DVHs were also evaluated. Results: Dose–volume histograms of 21 OARs in nasopharyngeal cancer were predicted using the models. For each patient, 63 DVIs for all OARs were calculated. Using the 60 patient treatment plans in the testing dataset, 79% and 73% of the DVIs predicted using the CResDevNet and UNet models, respectively, were within 5% of the clinical values. The median value of the DVIs' mean absolute errors was 3.2 ± 2.5% and 3.7 ± 2.9% for the CResDevNet and UNet models, respectively. The average dice similarity coefficient for all OARs was 0.965 using the CResDevNet model and 0.958 using the UNet model. Conclusions: A deep learning model was developed for predicting achievable DVHs of OARs. The prediction accuracy of the CResDevNet model was evaluated using a planning database of nasopharyngeal cancer cases and shown to be more accurate than the UNet model. Prediction accuracy was also higher for larger‐volume OARs. The model can be used for automation of inverse planning and quality assessment of individual treatment plans. [ABSTRACT FROM AUTHOR]

Purpose: To examine general dose–volume characteristics in Gamma Knife (GK) plans which may be associated with higher tumor control probability (TCP) and equivalent uniform dose (EUD) using characteristic curve sets. Methods: Two sets of dose–volume histograms (DVHs) were exported alongside an analytical purpose‐generated DVH: (a) single‐shot large collimator (8 or 16 mm) emulated with multiple shots of 4 mm collimator. (b) shot‐within‐shot (SWS) technique with isodose lines (IDLs) of 40–75%. TCP, average dose, EUD in single‐fraction (EUDT) and 2 Gy fractionated regimens (EUDR) were examined for trends with cumulative DVH (cDVH) shape as calculated using a linear‐quadratic cell survival model (α/β = 10.0 Gy, N0 = 1 × 106) with both α = 0.20 Gy−1 and α = 0.23 Gy−1. Results: Using α = 0.20 Gy−1 (α = 0.23 Gy−1), plans in the analytical set with higher shoulder regions had TCP, EUDT, EUDR increased by 180%, 5.9%, 10.7% (11.2%, 6.3%, 10.0%), respectively. With α = 0.20 Gy−1 (α = 0.23 Gy−1), plans with higher heels had TCP, EUDT, EUDR increased by 4.0%, <1%, <1% (0.6%, <1%, <1%), respectively. In emulating a 16 (8) mm collimator, 64 (12) shots of the small collimators were used. Plans based on small collimators had higher shoulder regions and, with α = 0.20 Gy−1 (α = 0.23 Gy−1), TCP, EUDT, EUDR was increased up to 351.4%, 5.0%, 8.8% (270.4%, 5.0%, 6.8%) compared with the single‐shot large collimator. Delivery times ranged from 10.2 to 130.3 min. The SWS technique used 16:8 mm collimator weightings ranging from 1:2 to 9.2:1 for 40–75% IDL. With α = 0.20 Gy−1 (α = 0.23 Gy−1), the 40% IDL plan had the highest shoulder with increased TCP, EUDT, EUDR by 130.7%, 9.6%, 17.1% (12.9%, 9.1%, 16.4%) over the 75% IDL plan. Delivery times ranged 6.9–13.8 min. Conclusions: The magnitude of the shoulder region characteristic to GK cDVHs may be used to rapidly identify superior plan among candidates. Practical issues such as delivery time may require further consideration. [ABSTRACT FROM AUTHOR]

Introduction: To evaluate the clinical and dosimetric parameters that increase the risk of radiation pneumonitis (RP) in locally advanced non‐small cell lung cancer (NSCLC) patients treated with concomitant chemoradiotherapy of nationwide multicentric data analysis. Methods: All data of 268 patients who underwent definitive chemoradiotherapy were retrospectively collected from eight institutes participating in this study. Patient, tumor and treatment‐related factors and dosimetric parameters were analyzed for grade ≥2 RP. The toxicity scoring system of The Radiation Therapy Oncology Group used for grading the severity of pneumonitis. A relationship with the risk of RP with potential predictive factors were evaluated by univariate and multivariate analyses. A recursive partition analysis (RPA) was applied to stratify patients according to the risk of developing RP. Results: There were 90 (33.6%) patients who had grade ≥2 RP. The median time to pneumonitis after treatment was 4 months (range:1‐6 months). In univariate analysis, diabetes mellitus (DM), use of cisplatin/etoposide, total and daily radiotherapy (RT) fraction dose, the planning target volume (PTV) size, mean lung dose, V5, V10 and RT technique were associated with the development of pneumonitis. In multivariate analysis, only DM (P = 0.008) was found to be independent risk factors for RP. According to RPA, the risk of developing RP was highest in patients with DM. Conclusions: In our study, besides the known dosimetric factors, DM was found to be the most important risk factor causing RP development in multivariate analysis and RPA. The risk is tripled compared to patients without DM. [ABSTRACT FROM AUTHOR]